Record investment surges into start-ups as entrepreneurs and investors bet on rapid growth, but a growing number of scientists warn that many companies are setting unrealistically aggressive timelines for achieving major breakthroughs. Concerns center on whether ambitious projections—particularly in fields like biotechnology and artificial intelligence—are being driven by market hype rather than rigorous scientific validation. Experts caution that overoptimism could lead to wasted resources, failed products, or even ethical risks if expectations outpace reality. The debate highlights a tension between innovation-driven funding and the need for cautious, evidence-based development in cutting-edge industries.
Start-ups are attracting record investments. Some scientists think their timelines are far too optimistic
